Research progress on the role and clinical application of Siglecs in tumor immunity / 细胞与分子免疫学杂志
Chinese Journal of Cellular and Molecular Immunology
;
(12): 1125-1131, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-1009464
ABSTRACT
Lectins are proteins responsible for recognizing the signals of sugar molecules in the body. Sialic acid-binding immunoglobulin-like lectins (Siglecs) regulate the innate and adaptive immune responses in the tumor microenvironment by recognizing the glycan structure containing sialic acid and mediating downstream signals through immune receptor tyrosine inhibitory motifs. In recent years, a variety of tumor treatment strategies targeting the sialic acid-Siglecs axis have been introduced, including sialoglycoprotein-mediated drug delivery and antibody mediated inhibition of Siglecs from recognizing tumor surface ligands. In the future, by combining with glycoprotein nanotherapy, antibody therapy and gene therapy, Siglecs can be used to accurately locate tumor targets and release the anti-tumor immunity, so as to achieve the purpose of effective cure of tumors.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Inmunoglobulinas
/
Receptores Inmunológicos
/
Ácido N-Acetilneuramínico
/
Lectinas Similares a la Inmunoglobulina de Unión a Ácido Siálico
/
Ligandos
Idioma:
Chino
Revista:
Chinese Journal of Cellular and Molecular Immunology
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS